NASDAQ: AVLNAvalyn Pharma Inc Stock
$28.79-0.52 (-1.77%)
Updated Jul 31, 2026
AVLN Price
$28.79
Fair Value Price
$1.21
Market Cap
$1.28B
52 Week Low
$24.15
52 Week High
$33.32
P/E
N/A
P/B
-4.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.11
Operating Cash Flow
N/A
Beta
-0.17
Next Earnings
Sep 2, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AVLN Overview
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVLN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVLN
Ranked#155 of 460
Ranked#155 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $252.86 | A | |
| $11.21 | A | |
| $114.49 | A |
Be the first to know about important AVLN news, forecast changes, insider trades & much more!
AVLN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVLN ($28.79) is overvalued by 2,276.83% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVLN ($28.79) is not significantly undervalued (2,276.83%) relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVLN's short-term assets ($129.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more AVLN due diligence checks available for Premium users.
Valuation
AVLN fair value
Fair Value of AVLN stock based on Discounted Cash Flow (DCF)
Price
$28.79
Fair Value
$1.21
Overvalued by
2,276.83%
AVLN ($28.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVLN ($28.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.83x
Industry
5.23x
AVLN's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.9M
Profit Margin
0%
Assets to liabilities
Assets
$135.7M
Liabilities
$27.7M
Debt to equity
-0.11
AVLN's short-term assets ($129.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVLN's short-term assets ($129.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.9M
Investing
$55.0M
Financing
$14.9M
AVLN vs Biotech Stocks
Avalyn Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.